February 12, 2026 4:37pm

Initial jobless claims moved lower last week after a temporary weather-induced bump, the Labor Department

It ain’t ended, CPI is on Friday’s agenda

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

 

RMi Pre-opening: Econs and earnings combined are toxic … https://www.regmedinvestors.com/articles/14310

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Thursday: The Dow closed DOWN -669.42 points or -1.34%, the S&P closed DOWN -108.71 points or -1.57% while the Nasdaq closed DOWN -469.319 points or -2.04%

  • Theme of the session: investors continued to shift away from technology names

Thursday’s (my) 40-company covered sector’s advance/decline line opened negative with 5 incliners, 33 decliners and 2 flats, ending with a negative close of 7 incliners, 31 decliners and 2 flats

  •  Stocks dropped as investors began to worry about the negative side of the artificial intelligence buildout, which threatens to disrupt the business models of whole industries and raise unemployment. <CNBC>

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • First-time filings for unemployment benefits totaled a seasonally adjusted 227,000 for the week ended Feb. 7, down 5,000 from the previous period’s upwardly revised number. The figure was slightly higher than the consensus estimate for 225,000. Continuing claims, which run a week behind, rose 21,000 to 1.86 M. Following a period where longer-running claims were running higher, the 4-week moving average fell to its lowest level since 10/5/24.
  • Existing home sales recorded a sizable drop in January, falling 8.4% from December to 3.91 million; larger than expected, as economists had anticipated a 4.6% decline to 4.15 M.
  • Investors are now gearing up for Friday’s inflation reading. Economists are expecting the consumer price index for January to show a 0.3% increase for both headline and core, which excludes food and energy prices.

The CBOE Fear (VIX) index, Thursday closed at 20.90, after Wednesday’s 17.71, Tuesday’s 17.23, Monday’s 17.44, Friday’s 17.75 and last Thursday’s 21.63

Metrics: Thursday …

  • The RUT was down -56.68 points or -2.12%,
  • The XLV was down -0.21 points or -0.13%,
  • The NBI was down -62.58 points or -1.06%;
  • The XBI was down -1.47 points or -1.18%
  • The IWM was down -5.39 or -2.03%;
  • The IBB was down -2.06 points or -1.19%,
  • The VIX was up +3.25 points or +18.37% at to 20.90

 

Q1/26 February – 6 negative and 3 positive sessions

  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Thursday Closing UP (7 of 7) 

  • Vertex (VRTX +$3.78 after Wednesday’s -$2.24, Tuesday’s -$7.39 and Monday’s -$7.05),
  • Beam Therapeutics (BEAM +$0.94 and Wednesday’s -$0.96),
  • Arrowhead Pharmaceuticals (ARWR +$0.83 after Wednesday’s -$1.37, Tuesday’s +$0.32 and Monday’s -$1.88),
  • CRISPR Therapeutics (CRSP +$0.61),
  • Fate Therapeutics (FATE +$0.03 and Wednesday’s +$0.10),
  • Rocket Therapeutics (RCKT +$0.01),
  • Brainstorm Cell Therapeutics (BCLI +$0.0069)

Flat (2)

  • Generation Bio (GBIO) – acquired
  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Wednesday’s $0.00, Tuesday’s +$0.10 <with 660 shares> and Monday’s $0.00),

Thursday’s Closing DOWN (10 of 31): 

  • Alnylam Pharmaceuticals (ALNY -$13.27 after Wednesday’s -$1.23 after Tuesday’s +$2.98 after Monday’s -$8.16),
  • IQIA Holdings (IQV -$8.26 after Wednesday’s -$5.29 after Tuesday’s -$10.22 after Monday’s +$5.27),
  • BioNTech (BNTX -$3.62 after Wednesday’s +$0.45 after Tuesday’s -$1.41 after Monday’s +$3.72),
  • Ionis Pharmaceuticals (IONS -$2.57 after Wednesday’s -$0.06 after Tuesday’s -$0.50 after Monday’s -$1.71),
  • uniQure NV (QURE -$1.74 after Wednesday’s -$0.60 after Tuesday’s -$1.34 after Monday’s +$0.40),
  • Supernus Therapeutics (SUPN -$1.49 after Wednesday’s +$0.13),
  • Mesoblast (MESO -$1.41 after Wednesday’s +$0.31 after Tuesday’s +$1.21 after Monday’s +$0.83),
  • AxoGen (AXGN -$1.29 after Wednesday’s -$0.61 after Tuesday’s +$0.58 after Monday’s -$1.00),
  • Dyne Therapeutics (DYN -$0.68),
  • BioLife Solutions (BLFS -$0.67),

 

The Bottom Line: More of the … WHY

C&GT sector bleeds share pricing yet again after the again

Indexes dived sharply lower Thursday as fears of AI-driven disruption prompted investors to rotate out of techy shares.

  • The mixed picture comes as investors search for clues to the sectors vulnerable to AI disruption, which spurred the recent meltdown in software stocks.
  • Trucking and logistics and real estate services stocks were the latest to get hit over concerns that artificial intelligence will impact those industries. <Yahoo Finance>

 

Investors also looked ahead to Friday’s inflation reading for clues on rate-cut bets, which were already dampened by a strong January jobs report.

 

Thursday’s Q4 and FY25 sector earnings releases should/could provide further insight into cell and gene therapy sector investor “feelings”

Earnings release dates:

  • 2/13 – Moderna (MRNA)
  • Tuesday - 2/24 – AxoGen (AXGN)
  • Wednesday – 2/25 – Ionis Pharmaceuticals (IONS) and Sarepta Theoretics (SRPT)

 

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

February – 2nd week

  • 2/12 – Thursday closed negative with 7 incliners, 33 decliners and 2 flats
  • 2/11 - Wednesday closed negative with 12 incliners, 25 decliners and 3 flats
  • 2/10 - Tuesday closed negative with 19 incliners, 20 decliners and 1 flat
  • 2/9 -Monday closed positive with 23 incliners, 14 decliners and 3 flats

February – 1st week

  • 2/6 – Friday closed positive with 35 incliners, 5 decliners and 0 flat
  • 2/5 -Thursday closed negative with 2 incliners, 36 decliners and 2 flats
  • 2/4 -Wednesday closed negative with 10 incliners, 29 decliners and 1 flat               
  • 2/3 -Tuesday closed negative with 18 incliners, 21 decliners and 1 flat      
  • 2/2 -Monday closed positive with 29 incliners, 10 decliners and 1 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Thursday: Vertex (VRTX), Beam Therapeutics (BEAM) and Arrowhead Pharmaceuticals (ARWR)
  • Wednesday: BioNTech (BNTX), Mesoblast (MESO) and Entrada Therapeutics (TRDA)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Mesoblast (MESO) and AxoGen (AXGN)
  • Monday: IQIA Holdings (IQV), BioNTech (BNTX) and Mesoblast (MESO)

The worst three (3) in the session: Losers

  • Thursday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and BioNTech (BNTX)
  • Wednesday: IQIA Holdings (IQV), Vertex (VRTX) and Moderna (MRNA) 
  • Tuesday: IQIA Holdings (IQV), Vertex (VRTX) and Regenxbio (RGNX)
  • Monday: BioNTech (BNTX), Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.